Generated: May 30, 2017
|Title:||Controlled/modified release oral methylphenidate formulations|
|Abstract:||The invention is directed to oral modified/controlled release methylphenidate formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release methylphenidate formulations, and the duration of effect falls rapidly at the end of the dosing interval so as not to affect the appetite of the patient at dinner nor the patient's sleep thereafter.|
|Inventor(s):||Goldenheim; Paul D. (Wilton, CT), Sackler; Richard S. (Greenwich, CT), Krishnamurthy; Thinnayam N. (Ontario, CA), Darke; Andrew (Ontario, CA), Oshlack; Benjamin (New York, NY)|
|Assignee:||Euro-Celtique, S.A. (Luxembourg, LU)|
|Filing Date:||Dec 16, 1999|
|Claims:||1. An oral dosage form comprising an effective amount of methylphenidate or a pharmaceutically acceptable salt thereof and at least one release modifying material which causes the formulation to provide an in-vitro dissolution of the drug of from about 0 to about 45% released after 0.25 hour; from about 10 to about 50% released after about 1 hour; from about 30 to about 80% drug released after about 4 hours; not less than about 65% drug released after 8 hours; and not less than about 80% of the drug released after about 12 hours; the oral dosage form when orally administered to a human patient further providing a time to maximum plasma concentration at about 0.5 to about 2 hours after oral administration, and a duration of effect which lasts from about 8 to about 10 hours after oral administration, wherein the plasma concentration of the drug rapidly falls at about 8 to about 10 hours after oral administration to a level which is below the minimum effective plasma concentration. |
2. The oral dosage form of claim 1, which when orally administered provides a peak plasma concentration from about 4 ng/ml to about 6.5 ng/ml per 20 mg dose of methylphenidate contained in the oral dosage form.
3. The oral dosage form of claim 1, which when orally administered provides a peak plasma concentration from about 5 ng/ml to about 6.5 ng/ml per 20 mg dose of methylphenidate contained in the oral dosage form.
4. The oral dosage form of claim 1, wherein the peak plasma concentration is from about 1.0 to about 2.0 times the plasma concentration of methylphenidate provided by the formulation at about 9 hours after oral administration.
5. The oral dosage form of claim 1, wherein the peak plasma concentration is from about 1.0 to about 1.7 times the plasma concentration of methylphenidate provided by the formulation at about 9 hours after oral administration.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.